ADX-2191 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 90 | Retinitis pigmentosa | 1 |
90. Retinitis pigmentosa
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05392179 (ClinicalTrials.gov) | July 14, 2022 | 28/3/2022 | A Study in Subjects With Retinitis Pigmentosa | An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: ADX-2191 | Aldeyra Therapeutics, Inc. | NULL | Recruiting | 18 Years | N/A | All | 8 | Phase 2 | United States |